Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...
Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...
Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...
Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...
Revenue Guidance (2025): $610 million to $630 million, representing 0% to 3% growth over 2024. 10x Genomics Inc (NASDAQ:TXG) ...
A team of medical professionals in surgical scrubs analysing research data in a laboratory. ARK Investment Management’s Q3 Stake Value: $242.7 million Number of Hedge Fund Holders: 29 10x Genomics, ...
PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...
The Chromium Xo, being more affordable than some of the company's other offerings, could attract a broader customer base, including smaller research labs and institutions with limited budgets. This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback